<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849469</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb22841-01</org_study_id>
    <secondary_id>DUET-4</secondary_id>
    <nct_id>NCT03849469</nct_id>
  </id_info>
  <brief_title>A Study of XmAb®22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors</brief_title>
  <acronym>DUET-4</acronym>
  <official_title>A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study&#xD;
      designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy&#xD;
      and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics,&#xD;
      immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with&#xD;
      pembrolizumab in subjects with select advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.</measure>
    <time_frame>56 Days</time_frame>
    <description>Rates of treatment-related adverse events (AEs), graded by CTCAE v4.03, and additionally categorized as either immune-related or non-immune AEs.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Melanoma</condition>
  <condition>Cervical Carcinoma</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <condition>Gastric or Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <condition>Prostate Carcinoma</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <condition>Squamous Cell Anal Cancer</condition>
  <condition>Squamous Cell Penile Carcinoma</condition>
  <condition>Squamous Cell Vulvar Carcinoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: XmAb®22841 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XmAb®22841</intervention_name>
    <description>Monoclonal bispecific antibody</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab (Keytruda®)</intervention_name>
    <description>FDA-approved humanized monoclonal antibody</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PART A (Dose Escalation Cohorts)&#xD;
&#xD;
          1. All subjects' cancer must have progressed after treatment with all available therapies&#xD;
             that are known to confer clinical benefit, or are intolerant to treatment, or refuse&#xD;
             standard treatment.&#xD;
&#xD;
          2. All subjects must have adequate archival tumor, or give consent to a fresh tumor&#xD;
             biopsy.&#xD;
&#xD;
          3. Subjects have an ECOG performance status of 0-1.&#xD;
&#xD;
          4. Subjects in monotherapy and combination therapy cohorts must have histologically or&#xD;
             cytologically confirmed advanced or metastatic solid tumors, including the following:&#xD;
&#xD;
               1. Melanoma&#xD;
&#xD;
               2. Cervical carcinoma&#xD;
&#xD;
               3. Pancreatic carcinoma&#xD;
&#xD;
               4. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2&#xD;
                  negative (TNBC)&#xD;
&#xD;
               5. Hepatocellular carcinoma&#xD;
&#xD;
               6. Urothelial carcinoma&#xD;
&#xD;
               7. Squamous cell carcinoma of the head and neck (HNSCC)&#xD;
&#xD;
               8. Nasopharyngeal carcinoma (NPC)&#xD;
&#xD;
               9. Renal cell carcinoma&#xD;
&#xD;
              10. Colorectal carcinoma or endometrial carcinoma&#xD;
&#xD;
              11. Small cell lung carcinoma or NSCLC&#xD;
&#xD;
              12. Gastric or gastroesophageal junction adenocarcinoma&#xD;
&#xD;
              13. Prostate adenocarcinoma&#xD;
&#xD;
              14. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer&#xD;
&#xD;
              15. Intrahepatic cholangiocarcinoma&#xD;
&#xD;
          5. Subjects in the combination cohorts in Part A with XmAb22841 and pembrolizumab may&#xD;
             have an advanced solid tumor that either:&#xD;
&#xD;
               -  has progressed after treatment with all available therapies that are known to&#xD;
                  confer clinical benefit, or is intolerant or has refused standard treatment (as&#xD;
                  for the XmAb22841 monotherapy cohorts), or&#xD;
&#xD;
               -  is of a tumor type for which pembrolizumab is an approved indication and has not&#xD;
                  previously been treated with an agent targeting PD1 or PDL1.&#xD;
&#xD;
        PART B (Dose Expansion Cohorts)&#xD;
&#xD;
        XmAb22841 Single Agent Cohort&#xD;
&#xD;
        1. Must have histologically or cytologically confirmed advanced or metastatic solid tumor&#xD;
        that has progressed after treatment with all available therapies that are known to confer&#xD;
        clinical benefit, or are intolerant to treatment, or refuse standard treatment. Eligible&#xD;
        tumor types include the following:&#xD;
&#xD;
          1. Anti-PD1 refractory melanoma (or any uveal melanoma)&#xD;
&#xD;
          2. Anti-PD1 refractory NSCLC&#xD;
&#xD;
          3. Anti-PD1 refractory renal cell carcinoma (with clear cell component)&#xD;
&#xD;
          4. Anti-PD1 refractory urothelial carcinoma&#xD;
&#xD;
          5. Head and neck squamous cell carcinoma&#xD;
&#xD;
          6. Hepatocellular carcinoma&#xD;
&#xD;
          7. Gastric adenocarcinoma&#xD;
&#xD;
          8. Cervical carcinoma&#xD;
&#xD;
          9. Breast carcinoma that is estrogen receptor, progesterone receptor, and HER2 negative&#xD;
             (TNBC)&#xD;
&#xD;
         10. Epithelial ovarian cancer&#xD;
&#xD;
         11. Nasopharyngeal carcinoma&#xD;
&#xD;
         12. Squamous cell anal carcinoma&#xD;
&#xD;
         13. Squamous cell penile carcinoma&#xD;
&#xD;
         14. Squamous cell vulvar carcinoma&#xD;
&#xD;
        XmAb22841 + Pembrolizumab Cohorts&#xD;
&#xD;
          1. Anti-PD-1 refractory melanoma (excluding uveal melanoma)&#xD;
&#xD;
          2. Anti-PD-1 naïve melanoma (excluding uveal melanoma)&#xD;
&#xD;
          3. Anti-PD-1 refractory NSCLC&#xD;
&#xD;
          4. Anti-PD1 naïve NSCLC&#xD;
&#xD;
             a. Must be PD-L1 high (TPS ≥ 50%), with no EGFR or ALK aberrations&#xD;
&#xD;
          5. Anti-PD1 naïve urothelial carcinoma&#xD;
&#xD;
               1. Must be PDL1 positive (CPS of ≥ 10), or ineligible for any platinum-containing&#xD;
                  chemotherapy regardless of PDL1 status; or&#xD;
&#xD;
               2. Had disease progression within 12 months of neoadjuvant or adjuvant treatment&#xD;
                  with platinum-containing chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with an investigational anti-LAG3 therapy.&#xD;
&#xD;
          2. Treatment with any CTLA4 antibody within 16 weeks of the start of study drug for&#xD;
             Cohorts 1M, 2M, 3M, 1P, and 2P; within 8 weeks for Cohorts 4M, 5M, 3P, 4P and 4Pi; and&#xD;
             within 3 weeks for Cohorts 6M, 7Mi, 7M, 5P, and 6P.&#xD;
&#xD;
          3. Systemic antineoplastic therapy, unconjugated antibody therapy within 4 weeks of the&#xD;
             first dose of study treatment; or radiotherapy within 2 weeks of the first dose of&#xD;
             study treatment; or small molecule kinase inhibitors within 6 elimination half-lives&#xD;
             of the first dose of study treatment.&#xD;
&#xD;
          4. Have received prior therapy with an anti-PD1, anti-PDL1, or anti PDL2 agent or with an&#xD;
             agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA4, OX&#xD;
             40, CD137) AND were permanently discontinued from that treatment due to an irAE.&#xD;
&#xD;
          5. Failure to recover from any irAE from prior cancer therapy to Grade ≤ 1.&#xD;
&#xD;
          6. Failure to recover from any other toxicity (other than immune-related toxicity)&#xD;
             related to previous anticancer treatment to Grade ≤ 2.&#xD;
&#xD;
          7. Active known or suspected autoimmune disease (except that subjects are permitted to&#xD;
             enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to&#xD;
             an autoimmune condition that is treatable with hormone replacement therapy only;&#xD;
             psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed&#xD;
             without systemic therapy; or arthritis that is managed without systemic therapy beyond&#xD;
             oral acetaminophen and non-steroidal anti-inflammatory drugs).&#xD;
&#xD;
          8. Receipt of an organ allograft.&#xD;
&#xD;
          9. Treatment with antibiotics within 14 days prior to first dose of study drug.&#xD;
&#xD;
         10. Participants with known HIV.&#xD;
&#xD;
         11. Participants with known chronic hepatitis B virus (HBV) infection treated for less&#xD;
             than 3 months prior to study enrollment and/or with a detectable HBV viral load; or&#xD;
             hepatitis C virus (HCV) infection that has been treated for less than 4 weeks prior to&#xD;
             study enrollment and/or with a detectable HCV viral load; or active HBV/HCV&#xD;
             coinfection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Thompson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Xencor, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Thompson, MD, PhD</last_name>
    <phone>619-517-7381</phone>
    <email>bthompson@xencor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Sarot</last_name>
    <phone>858-245-9419</phone>
    <email>asarot@xencor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSD Medical Center - Encinitas</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koman Family Outpatient Pavilion</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Altman Clinical and Translational Research Institute Building (ACTRI)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Perlman Medical Offices</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center - Hillcrest</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Rancho Bernardo Medical Office</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center - Vista</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Health Care Center, Chestnut Hill</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical School</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania - Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research - Medical City</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah, Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DUET-4</keyword>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Metastatic solid tumors</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Hepatocellular/Liver Cancer</keyword>
  <keyword>Urothelial Cancer</keyword>
  <keyword>Renal Cell Cancer</keyword>
  <keyword>Squamous Cell Carcinoma of the Head and Neck</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastroesophageal Junction Cancer</keyword>
  <keyword>Lymphocyte-activation gene 3 (LAG3)</keyword>
  <keyword>Cytotoxic T-lymphocyte-associated protein 4 (CTLA4)</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Epithelial ovarian cancer</keyword>
  <keyword>Fallopian tube cancer</keyword>
  <keyword>Primary peritoneal carcinoma</keyword>
  <keyword>Intrahepatic cholangiocarcinoma</keyword>
  <keyword>Squamous Cell Anal Carcinoma</keyword>
  <keyword>Squamous Cell Penile Carcinoma</keyword>
  <keyword>Squamous Cell Vulvar Carcinoma</keyword>
  <keyword>Colorectal Carcinoma</keyword>
  <keyword>Endometrial Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

